Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

527
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
527
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

151
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
151
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

143
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
143
Lipid Absorption01:24

Lipid Absorption

421
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
421

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rational Design of Small-Molecule Stabilizers of Human Fumarylacetoacetate Hydrolase for the Treatment of Tyrosinemia Type I.

Journal of medicinal chemistry·2026
Same author

Biological Signatures of Inflammation Biomarkers Identified Using Data Reduction Methods in Adult Population: A Scoping Review Protocol.

Health science reports·2026
Same author

A small molecule inhibitor of ARF GTPase protein 1 limits liver and colon cancer cell growth and metastasis.

Cell death & disease·2026
Same author

Aminolevulinate inhibition of human coproporphyrinogen oxidase clarifies coproporphyrin III accumulation in porphyrias.

Bioscience reports·2026
Same author

Methionine Adenosyltransferase 1A and S-Adenosylmethionine in Alcohol-Associated Liver Disease.

Antioxidants (Basel, Switzerland)·2025
Same author

Correction to "Benchtop Proton NMR Spectroscopy for High-Throughput Lipoprotein Quantification in Human Serum and Plasma".

Analytical chemistry·2025

Related Experiment Video

Updated: Jun 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

849

Dysfunctional VLDL metabolism in MASLD.

Urko M Marigorta1,2, Oscar Millet3, Shelly C Lu4

  • 1Integrative Genomics Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.

Npj Metabolic Health and Disease
|July 25, 2024
PubMed
Summary

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) presents three distinct subtypes (metabotypes) with varying risks for cardiovascular disease (CVD) and liver cancer. Understanding these lipidomic profiles is key to personalized risk assessment and treatment strategies.

Keywords:
HepatologyLiver diseasesMetabolomics

More Related Videos

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.4K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Related Experiment Videos

Last Updated: Jun 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

849
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.4K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Area of Science:

  • Lipidomics
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Cardiovascular Disease (CVD) risk stratification

Background:

  • Lipidomics reveals extensive lipid diversity in mammalian tissues, crucial for cellular function.
  • MASLD, associated with obesity and diabetes, involves liver instability in lipid metabolism, misinterpreting energy status.
  • Serum lipidomic studies identify three distinct MASLD metabotypes (A, B, C) with differing very low-density lipoprotein (VLDL) secretion and triglyceride (TG) levels.

Purpose of the Study:

  • To examine the regulation of VLDL secretion by S-adenosylmethionine.
  • To explore differential CVD and hepatic cancer risks across MASLD metabotypes.
  • To discuss potential future research directions for understanding MASLD heterogeneity.

Main Methods:

  • Serum lipidomic profiling to delineate MASLD metabotypes.
  • Analysis of VLDL secretion regulation by S-adenosylmethionine.
  • Comparative assessment of CVD and hepatic cancer risks among MASLD subtypes.

Main Results:

  • MASLD-A: lower VLDL secretion, lower TG, reduced CVD risk.
  • MASLD-C: increased VLDL secretion, higher TG, elevated CVD risk.
  • MASLD-B: intermediate features, reflecting a mixed metabolic state.

Conclusions:

  • MASLD exhibits significant heterogeneity, with distinct metabotypes linked to differential health risks.
  • S-adenosylmethionine plays a role in VLDL secretion regulation, contributing to MASLD phenotypes.
  • Further research integrating genetic and lipidomic data is needed to understand MASLD heterogeneity and guide clinical strategies.